Cargando…
Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host’s Innate Antiviral Immunity to Attack Tumor Cells
One of the major hurdles for cancer immunotherapy is the host’s innate antiviral defense mechanisms. They include innate immune cells, such as natural killer (NK) cells and macrophages, which can be recruited within hours to the site of injection to clear the introduced oncolytic viruses. Here, we r...
Autores principales: | Fu, Xinping, Tao, Lihua, Wu, Wanfu, Zhang, Xiaoliu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530262/ https://www.ncbi.nlm.nih.gov/pubmed/33024817 http://dx.doi.org/10.1016/j.omto.2020.09.002 |
Ejemplares similares
-
Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles
por: Fu, Xinping, et al.
Publicado: (2018) -
An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites
por: Fu, Xinping, et al.
Publicado: (2014) -
Enhancing The Bystander Killing Effect Of An Oncolytic HSV By Arming It With A Secretable Apoptosis Activator
por: Loya, Shana Marie Williamson, et al.
Publicado: (2015) -
Evasion of host antiviral innate immunity by HSV-1, an update
por: Su, Chenhe, et al.
Publicado: (2016) -
Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site
por: Fu, Xinping, et al.
Publicado: (2018)